Roberta Chapman
Cardiovascular Disease · Gloucester, VANPI 1942266168
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $128,752 of the $154,635 with a category attached, or 83.3%. 13 manufacturers reported payments, led by Novartis at 46.9% of the total. Reporting peaked in 2019 at $100,037 and has fallen 99.7% since, to $253 in 2025. Among cardiovascular disease clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 186 payments — averaging $831.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$73K
- AstraZeneca$27K
- Abiomed$24K
- Amgen$16K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$10K
- Abbott$3K
- plus $2K from 7 others
Across 45 payments — averaging $4127.23 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$65K
- Abbott$57K
- Livanova USA, Inc.$35K
- Novartis$28K
- Boehringer Ingelheim Pharma GmbH & Co.kg$306
What the payments were for
- Consulting fees$8,6056%
- Speaking & faculty fees$128,75283%
- Travel & lodging$12,0408%
- Food & beverage$5,2383%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 53 | $72,569 |
| AstraZeneca | 30 | $27,156 |
| Abiomed | 20 | $23,989 |
| Amgen | 20 | $16,065 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 25 | $10,280 |
| Abbott | 27 | $2,726 |
| Pfizer | 2 | $1,590 |
| Vifor Pharma, Inc. | 3 | $155 |
| Alnylam Pharmaceuticals Inc. | 2 | $28 |
| Medtronic | 1 | $21 |
| Boston Scientific | 1 | $21 |
| Atricure, Inc. | 1 | $17 |
| Nuwellis, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ENTRESTO$72,056
- FARXIGA$27,053
- Impella$23,804
- Repatha$15,800
- LifeVest$9,809
- VYNDAQEL$1,575
- HeartMate 3 Left Ventricular Dev$852
- CardioMEMS HF System$713
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$422
- HeartMate$137
- CARDIOMEMS$124
- Veltassa$108
How this compares
$154,635 in reported general payments places this provider in the 95th percentile of 548 cardiovascular disease providers in Virginia.
Other cardiovascular disease in Gloucester
- George VetrovecRichmond$2.3M
- Hamid TaheriManassas$501K
- Cyrus HadadiNorfolk$360K
- Michael AyersCharlottesville$305K
- David LimCharlottesville$264K
- Alexander TruesdellFalls Church$167K
- Antonio AbbateCharlottesville$161K
- Christopher OconnorFalls Church$161K
- Shaival KapadiaColonial Heights$115K
- Jamieson BourqueCharlottesville$104K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.